 Diana Cittelly
Concepts (216)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Brain Neoplasms | 12 | 2026 | 1331 | 3.010 |
Why?
| | Breast Neoplasms | 17 | 2026 | 2393 | 2.090 |
Why?
| | Receptor, trkB | 3 | 2026 | 39 | 1.600 |
Why?
| | MicroRNAs | 9 | 2018 | 686 | 1.200 |
Why?
| | Triple Negative Breast Neoplasms | 4 | 2019 | 218 | 1.040 |
Why?
| | Receptors, Estrogen | 3 | 2026 | 404 | 0.970 |
Why?
| | Receptor, trkA | 1 | 2026 | 18 | 0.970 |
Why?
| | Neural Cell Adhesion Molecules | 1 | 2026 | 38 | 0.950 |
Why?
| | Fibroblast Growth Factor 2 | 1 | 2026 | 94 | 0.920 |
Why?
| | Receptor, Fibroblast Growth Factor, Type 1 | 1 | 2026 | 58 | 0.920 |
Why?
| | Membrane Glycoproteins | 1 | 2026 | 499 | 0.790 |
Why?
| | Estradiol | 3 | 2019 | 515 | 0.780 |
Why?
| | Brain Edema | 1 | 2023 | 62 | 0.780 |
Why?
| | Cell Line, Tumor | 16 | 2026 | 3551 | 0.770 |
Why?
| | Astrocytes | 3 | 2026 | 228 | 0.760 |
Why?
| | Brain-Derived Neurotrophic Factor | 2 | 2026 | 154 | 0.750 |
Why?
| | Estrogens | 5 | 2026 | 367 | 0.750 |
Why?
| | Interleukin-13 Receptor alpha2 Subunit | 1 | 2021 | 5 | 0.700 |
Why?
| | Tamoxifen | 4 | 2016 | 193 | 0.660 |
Why?
| | Protein Kinase Inhibitors | 1 | 2026 | 981 | 0.610 |
Why?
| | Brain | 3 | 2026 | 2969 | 0.540 |
Why?
| | Gene Expression Regulation, Neoplastic | 11 | 2025 | 1450 | 0.530 |
Why?
| | bcl-X Protein | 3 | 2007 | 45 | 0.520 |
Why?
| | Heterografts | 2 | 2019 | 143 | 0.510 |
Why?
| | Progesterone | 3 | 2014 | 215 | 0.460 |
Why?
| | Progestins | 2 | 2014 | 66 | 0.450 |
Why?
| | Lung Neoplasms | 2 | 2026 | 2668 | 0.450 |
Why?
| | Paracrine Communication | 1 | 2015 | 67 | 0.440 |
Why?
| | Spinal Cord Injuries | 3 | 2007 | 235 | 0.430 |
Why?
| | Mice | 16 | 2026 | 18358 | 0.430 |
Why?
| | Cell Movement | 5 | 2026 | 963 | 0.420 |
Why?
| | Cell Proliferation | 5 | 2026 | 2514 | 0.400 |
Why?
| | Endothelial Cells | 1 | 2020 | 878 | 0.400 |
Why?
| | Xenograft Model Antitumor Assays | 6 | 2025 | 936 | 0.350 |
Why?
| | Kruppel-Like Transcription Factors | 1 | 2012 | 83 | 0.340 |
Why?
| | Antineoplastic Agents, Hormonal | 3 | 2016 | 196 | 0.340 |
Why?
| | Paclitaxel | 1 | 2012 | 259 | 0.340 |
Why?
| | Animals | 20 | 2026 | 38106 | 0.330 |
Why?
| | Ovarian Neoplasms | 2 | 2019 | 596 | 0.330 |
Why?
| | Hyaluronan Receptors | 3 | 2025 | 104 | 0.330 |
Why?
| | Aquaporin 4 | 2 | 2023 | 101 | 0.330 |
Why?
| | Genes, bcl-2 | 1 | 2010 | 22 | 0.320 |
Why?
| | Estrogen Antagonists | 1 | 2010 | 37 | 0.320 |
Why?
| | Drug Resistance, Neoplasm | 4 | 2019 | 883 | 0.320 |
Why?
| | Mammary Glands, Animal | 1 | 2010 | 128 | 0.300 |
Why?
| | Signal Transduction | 6 | 2026 | 5226 | 0.280 |
Why?
| | Helicobacter pylori | 3 | 2005 | 44 | 0.280 |
Why?
| | Indazoles | 2 | 2026 | 85 | 0.270 |
Why?
| | Apoptosis | 6 | 2020 | 2445 | 0.260 |
Why?
| | Radiosurgery | 2 | 2023 | 399 | 0.250 |
Why?
| | Benzamides | 2 | 2026 | 226 | 0.250 |
Why?
| | Humans | 31 | 2026 | 145785 | 0.230 |
Why?
| | Stem Cells | 1 | 2010 | 630 | 0.230 |
Why?
| | Immunohistochemistry | 5 | 2016 | 1723 | 0.230 |
Why?
| | Neoplasm Metastasis | 2 | 2020 | 688 | 0.230 |
Why?
| | Female | 24 | 2026 | 79045 | 0.220 |
Why?
| | Mucin 5AC | 1 | 2025 | 71 | 0.210 |
Why?
| | Transduction, Genetic | 2 | 2016 | 132 | 0.210 |
Why?
| | Cell Differentiation | 1 | 2012 | 2050 | 0.210 |
Why?
| | Mice, Nude | 3 | 2020 | 680 | 0.210 |
Why?
| | Gastritis | 2 | 2002 | 117 | 0.200 |
Why?
| | Ribonuclease III | 2 | 2016 | 43 | 0.200 |
Why?
| | Stomach Neoplasms | 2 | 2002 | 128 | 0.200 |
Why?
| | DEAD-box RNA Helicases | 2 | 2016 | 84 | 0.190 |
Why?
| | Tumor Microenvironment | 4 | 2020 | 735 | 0.190 |
Why?
| | Disease Progression | 2 | 2026 | 2865 | 0.190 |
Why?
| | Edema | 1 | 2023 | 125 | 0.190 |
Why?
| | Medical Oncology | 1 | 2026 | 340 | 0.190 |
Why?
| | Anoikis | 2 | 2012 | 31 | 0.190 |
Why?
| | Hydrocephalus | 1 | 2023 | 111 | 0.180 |
Why?
| | Peptic Ulcer | 1 | 2002 | 18 | 0.180 |
Why?
| | Mice, SCID | 2 | 2012 | 369 | 0.170 |
Why?
| | Neoplasm Invasiveness | 3 | 2020 | 508 | 0.170 |
Why?
| | Biomarkers, Tumor | 2 | 2020 | 1329 | 0.170 |
Why?
| | Estrogen Receptor alpha | 2 | 2014 | 151 | 0.160 |
Why?
| | 3' Untranslated Regions | 2 | 2012 | 149 | 0.160 |
Why?
| | DNA, Bacterial | 1 | 2002 | 320 | 0.160 |
Why?
| | Receptor, EphB4 | 1 | 2020 | 33 | 0.160 |
Why?
| | Precancerous Conditions | 1 | 2002 | 166 | 0.160 |
Why?
| | Ephrin-B2 | 1 | 2020 | 45 | 0.160 |
Why?
| | Neurons | 2 | 2026 | 1652 | 0.150 |
Why?
| | Neoplasms, Experimental | 1 | 2020 | 167 | 0.150 |
Why?
| | Transplantation, Heterologous | 2 | 2016 | 170 | 0.140 |
Why?
| | Poly(ADP-ribose) Polymerases | 1 | 2019 | 88 | 0.140 |
Why?
| | Gonadal Steroid Hormones | 1 | 2020 | 143 | 0.140 |
Why?
| | Phthalazines | 1 | 2019 | 63 | 0.140 |
Why?
| | Necrosis | 1 | 2019 | 244 | 0.130 |
Why?
| | Poly(ADP-ribose) Polymerase Inhibitors | 1 | 2019 | 134 | 0.130 |
Why?
| | Tryptophan | 1 | 2018 | 182 | 0.130 |
Why?
| | Antineoplastic Agents, Immunological | 1 | 2019 | 198 | 0.120 |
Why?
| | Glioblastoma | 1 | 2020 | 354 | 0.120 |
Why?
| | Piperazines | 1 | 2019 | 375 | 0.120 |
Why?
| | Cancer-Associated Fibroblasts | 1 | 2016 | 23 | 0.120 |
Why?
| | Luminescent Measurements | 1 | 2016 | 75 | 0.120 |
Why?
| | ErbB Receptors | 2 | 2020 | 635 | 0.120 |
Why?
| | Mice, Inbred BALB C | 1 | 2019 | 1261 | 0.120 |
Why?
| | Antibody Specificity | 1 | 2016 | 179 | 0.120 |
Why?
| | Prognosis | 2 | 2021 | 4330 | 0.110 |
Why?
| | Gene Knockdown Techniques | 1 | 2015 | 334 | 0.110 |
Why?
| | STAT5 Transcription Factor | 1 | 2014 | 50 | 0.110 |
Why?
| | Antibodies | 1 | 2016 | 397 | 0.100 |
Why?
| | Phenylthiohydantoin | 1 | 2014 | 44 | 0.100 |
Why?
| | Androgen Receptor Antagonists | 1 | 2014 | 35 | 0.100 |
Why?
| | Oligonucleotide Array Sequence Analysis | 3 | 2010 | 751 | 0.100 |
Why?
| | In Situ Hybridization | 2 | 2010 | 318 | 0.100 |
Why?
| | Rats | 4 | 2020 | 5585 | 0.100 |
Why?
| | Up-Regulation | 2 | 2016 | 848 | 0.100 |
Why?
| | Tubulin | 2 | 2012 | 146 | 0.100 |
Why?
| | Antigens, Bacterial | 2 | 2005 | 126 | 0.100 |
Why?
| | Cell Transformation, Neoplastic | 1 | 2015 | 337 | 0.100 |
Why?
| | Transfection | 2 | 2012 | 927 | 0.100 |
Why?
| | Androgen Antagonists | 1 | 2014 | 91 | 0.100 |
Why?
| | Rats, Sprague-Dawley | 3 | 2007 | 2525 | 0.090 |
Why?
| | MCF-7 Cells | 3 | 2020 | 133 | 0.090 |
Why?
| | Tumor Suppressor Proteins | 1 | 2014 | 322 | 0.090 |
Why?
| | Cells, Cultured | 1 | 2019 | 4151 | 0.080 |
Why?
| | Tumor Burden | 1 | 2012 | 325 | 0.080 |
Why?
| | Cell Adhesion | 1 | 2012 | 451 | 0.080 |
Why?
| | Blotting, Northern | 1 | 2010 | 203 | 0.080 |
Why?
| | Mice, Inbred NOD | 1 | 2012 | 616 | 0.080 |
Why?
| | Receptors, Steroid | 1 | 2010 | 42 | 0.080 |
Why?
| | Neoplastic Stem Cells | 1 | 2014 | 409 | 0.080 |
Why?
| | Cell Size | 1 | 2010 | 93 | 0.080 |
Why?
| | Neoplasms | 1 | 2026 | 2913 | 0.080 |
Why?
| | Phosphorylation | 2 | 2020 | 1708 | 0.080 |
Why?
| | Ovariectomy | 1 | 2010 | 166 | 0.080 |
Why?
| | Gene Expression Profiling | 1 | 2016 | 1777 | 0.070 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2010 | 979 | 0.070 |
Why?
| | CD146 Antigen | 2 | 2020 | 38 | 0.070 |
Why?
| | Mice, Inbred C57BL | 1 | 2019 | 5995 | 0.070 |
Why?
| | PC12 Cells | 1 | 2007 | 42 | 0.060 |
Why?
| | Blotting, Western | 2 | 2007 | 1184 | 0.060 |
Why?
| | Subcellular Fractions | 1 | 2007 | 73 | 0.060 |
Why?
| | In Situ Nick-End Labeling | 1 | 2007 | 120 | 0.060 |
Why?
| | Gene Products, tat | 1 | 2007 | 22 | 0.060 |
Why?
| | CD11b Antigen | 1 | 2007 | 60 | 0.060 |
Why?
| | Organelles | 1 | 2007 | 55 | 0.060 |
Why?
| | Neuroglia | 1 | 2007 | 174 | 0.060 |
Why?
| | Colombia | 2 | 2005 | 42 | 0.060 |
Why?
| | Helicobacter Infections | 1 | 2005 | 30 | 0.060 |
Why?
| | Adhesins, Bacterial | 1 | 2005 | 44 | 0.060 |
Why?
| | Drug Administration Schedule | 1 | 2007 | 782 | 0.050 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2007 | 849 | 0.050 |
Why?
| | Microglia | 1 | 2007 | 273 | 0.050 |
Why?
| | Protein Structure, Tertiary | 1 | 2007 | 855 | 0.050 |
Why?
| | Analysis of Variance | 1 | 2007 | 1300 | 0.050 |
Why?
| | Receptors, Progesterone | 2 | 2016 | 244 | 0.050 |
Why?
| | Neoplasm Transplantation | 2 | 2014 | 246 | 0.050 |
Why?
| | Proto-Oncogene Proteins c-bcl-2 | 1 | 2005 | 241 | 0.050 |
Why?
| | Behavior, Animal | 1 | 2007 | 520 | 0.050 |
Why?
| | Nerve Tissue Proteins | 1 | 2007 | 592 | 0.050 |
Why?
| | Gastrointestinal Diseases | 1 | 2005 | 222 | 0.050 |
Why?
| | Aromatase | 1 | 2023 | 37 | 0.050 |
Why?
| | Oncogene Proteins, Fusion | 1 | 2005 | 212 | 0.050 |
Why?
| | Duodenal Ulcer | 1 | 2002 | 12 | 0.050 |
Why?
| | Recovery of Function | 1 | 2007 | 716 | 0.050 |
Why?
| | Gastritis, Atrophic | 1 | 2002 | 5 | 0.040 |
Why?
| | Motor Activity | 1 | 2007 | 718 | 0.040 |
Why?
| | Societies, Medical | 1 | 2026 | 900 | 0.040 |
Why?
| | Bacterial Proteins | 2 | 2005 | 968 | 0.040 |
Why?
| | Genetic Markers | 1 | 2002 | 338 | 0.040 |
Why?
| | Chi-Square Distribution | 1 | 2002 | 528 | 0.040 |
Why?
| | Tropism | 1 | 2020 | 1 | 0.040 |
Why?
| | Gene Expression Regulation | 2 | 2007 | 2601 | 0.040 |
Why?
| | Macrophages | 1 | 2007 | 1507 | 0.040 |
Why?
| | Disease Models, Animal | 2 | 2007 | 4568 | 0.040 |
Why?
| | Blood-Brain Barrier | 1 | 2020 | 160 | 0.040 |
Why?
| | Polymerase Chain Reaction | 1 | 2002 | 1043 | 0.040 |
Why?
| | Time Factors | 2 | 2007 | 7134 | 0.040 |
Why?
| | Tumor Cells, Cultured | 1 | 2020 | 887 | 0.030 |
Why?
| | Tryptophan Oxygenase | 1 | 2018 | 33 | 0.030 |
Why?
| | Kynurenine | 1 | 2018 | 114 | 0.030 |
Why?
| | Cell Culture Techniques | 1 | 2020 | 375 | 0.030 |
Why?
| | Piperidines | 1 | 2019 | 222 | 0.030 |
Why?
| | Genetic Variation | 1 | 2002 | 977 | 0.030 |
Why?
| | Wnt Signaling Pathway | 1 | 2019 | 212 | 0.030 |
Why?
| | Male | 6 | 2007 | 73012 | 0.030 |
Why?
| | Genotype | 1 | 2002 | 1857 | 0.030 |
Why?
| | Epithelial-Mesenchymal Transition | 1 | 2018 | 220 | 0.030 |
Why?
| | Treatment Outcome | 2 | 2023 | 11794 | 0.030 |
Why?
| | Combined Modality Therapy | 1 | 2019 | 1271 | 0.030 |
Why?
| | Survival Rate | 1 | 2020 | 2094 | 0.030 |
Why?
| | Indoles | 1 | 2019 | 507 | 0.030 |
Why?
| | Keratin-5 | 1 | 2014 | 44 | 0.030 |
Why?
| | Fibroblasts | 1 | 2020 | 1028 | 0.030 |
Why?
| | Tosyl Compounds | 1 | 2014 | 17 | 0.030 |
Why?
| | HEK293 Cells | 1 | 2016 | 741 | 0.020 |
Why?
| | Anilides | 1 | 2014 | 84 | 0.020 |
Why?
| | Middle Aged | 5 | 2019 | 36309 | 0.020 |
Why?
| | Neurotrophin 3 | 1 | 2012 | 10 | 0.020 |
Why?
| | Autocrine Communication | 1 | 2012 | 38 | 0.020 |
Why?
| | Receptors, Androgen | 1 | 2014 | 149 | 0.020 |
Why?
| | Nitriles | 1 | 2014 | 211 | 0.020 |
Why?
| | Down-Regulation | 1 | 2014 | 618 | 0.020 |
Why?
| | Disease-Free Survival | 1 | 2014 | 770 | 0.020 |
Why?
| | Predictive Value of Tests | 1 | 2016 | 2123 | 0.020 |
Why?
| | Immunoblotting | 1 | 2010 | 295 | 0.020 |
Why?
| | Aged | 3 | 2019 | 26217 | 0.020 |
Why?
| | Real-Time Polymerase Chain Reaction | 1 | 2010 | 337 | 0.020 |
Why?
| | NF-kappa B | 1 | 2012 | 667 | 0.020 |
Why?
| | Adult | 4 | 2019 | 40882 | 0.020 |
Why?
| | Reproducibility of Results | 1 | 2016 | 3418 | 0.020 |
Why?
| | Magnetic Resonance Imaging | 1 | 2019 | 3916 | 0.010 |
Why?
| | Gene Expression | 1 | 2010 | 1478 | 0.010 |
Why?
| | Phosphopyruvate Hydratase | 1 | 2005 | 25 | 0.010 |
Why?
| | Genes, Bacterial | 1 | 2005 | 152 | 0.010 |
Why?
| | Retrospective Studies | 1 | 2023 | 17330 | 0.010 |
Why?
| | Cell Count | 1 | 2005 | 319 | 0.010 |
Why?
| | Virulence Factors | 1 | 2005 | 175 | 0.010 |
Why?
| | Cell Death | 1 | 2005 | 382 | 0.010 |
Why?
| | Oligodendroglia | 1 | 2005 | 190 | 0.010 |
Why?
| | Intracellular Signaling Peptides and Proteins | 1 | 2005 | 457 | 0.010 |
Why?
| | Interleukin-8 | 1 | 2002 | 269 | 0.010 |
Why?
| | Young Adult | 1 | 2016 | 14254 | 0.010 |
Why?
| | RNA, Messenger | 1 | 2005 | 2805 | 0.010 |
Why?
| | Adolescent | 1 | 2005 | 22577 | 0.000 |
Why?
|
|
Cittelly's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|